Claus Andersson

Claus Andersson is a Swedish businessman and the current General Partner at Sunstone Life Science Ventures. Claus has over 8 years of experience in the pharmaceutical industry, having served on the Board of Directors for Cantargia AB, Acarix, Cardior Pharmaceuticals GmbH, Forendo Pharma Ltd, and IO Biotech A/S.

Andersson began their career in 2013 with Cantargia AB, a company that develops new treatments for cancer. Claus served as a Member of the Board of Directors for Cantargia AB for 8 years, until they transitioned to Sunstone Life Science Ventures in 2021.

At Sunstone Life Science Ventures, Andersson is responsible for investments in early to mid-stage life science companies. Claus is a Board Observer for several portfolio companies, and they also serve on the Board of Directors for Affibody AB.

Claus Andersson has a Doctor of Philosophy (PhD) in Multivariate statistics - Chemometrics from Københavns Universitet - University of Copenhagen. Claus also has a MSc in Chemical Engineering from DTU - Technical University of Denmark.

Claus Andersson reports to Søren Lemonius, Managing General Partner. Claus Andersson works with Jacob Lange Moresco - Investment Director, Søren Rask Tange - Finance Director, and Merete Lundbye Møller - Venture Partner, General Counsel.